Evidence map›Paper›PMID 35371042›Full record

ArticleFrontiers in immunology2022

Evaluation of Spike Protein Epitopes by Assessing the Dynamics of Humoral Immune Responses in Moderate COVID-19.

Lingyun Chen, Pengfei Pang, Huan Qi, Keqiang Yan, Yan Ren, Mingliang Ma, Ruyin Cao, Hua Li, Chuansheng Hu, Yang Li and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Lingyun ChenCollege of Life Science, University of Chinese Academy of Sciences, Beijing, China.
Pengfei PangCenter for Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
Huan QiShanghai Center for Systems Biomedicine, Shanghai Jiaotong University, Shanghai, China.
Keqiang YanCollege of Life Science, University of Chinese Academy of Sciences, Beijing, China.
Yan RenDepartment of Proteomics, Beijing Genomics Institution, Shenzhen, China.
Mingliang MaShanghai Center for Systems Biomedicine, Shanghai Jiaotong University, Shanghai, China.
Ruyin CaoDepartment of Proteomics, Beijing Genomics Institution, Shenzhen, China.
Hua LiState Key laboratory for Oncogenes and Bio-ID Center, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Chuansheng HuState Key laboratory for Oncogenes and Bio-ID Center, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Yang LiShanghai Center for Systems Biomedicine, Shanghai Jiaotong University, Shanghai, China.
Jun XiaCollege of Life Science, University of Chinese Academy of Sciences, Beijing, China.
Danyun LaiShanghai Center for Systems Biomedicine, Shanghai Jiaotong University, Shanghai, China.
Yuliang DongDepartment of Proteomics, Beijing Genomics Institution, Shenzhen, China.
Hewei JiangShanghai Center for Systems Biomedicine, Shanghai Jiaotong University, Shanghai, China.
Hainan ZhangShanghai Center for Systems Biomedicine, Shanghai Jiaotong University, Shanghai, China.
Hong ShanCenter for Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
Shengce TaoShanghai Center for Systems Biomedicine, Shanghai Jiaotong University, Shanghai, China.
Siqi LiuCollege of Life Science, University of Chinese Academy of Sciences, Beijing, China.
Shanghai Jiao Tong University · CNBGI Group (China) · CNUniversity of Chinese Academy of Sciences · CNState Key Laboratory of Oncogene and Related Genes · CNFifth Affiliated Hospital of Sun Yat-sen University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The spike protein (S) of SARS-CoV-2 is a major target for diagnosis and vaccine development because of its essential role in viral infection and host immunity. Currently, time-dependent responses of humoral immune system against various S protein epitopes are poorly understood. In this study, enzyme-linked immunosorbent assay (ELISA), peptide microarray, and antibody binding epitope mapping (AbMap) techniques were used to systematically analyze the dynamic changes of humoral immune responses against the S protein in a small cohort of moderate COVID-19 patients who were hospitalized for approximately two months after symptom onset. Recombinant truncated S proteins, target S peptides, and random peptides were used as antigens in the analyses. The assays demonstrated the dynamic IgM- and IgG recognition and reactivity against various S protein epitopes with patient-dependent patterns. Comprehensive analysis of epitope distribution along the

Indexed as

COVID-19Antibodies, ViralEpitopesHumansImmunity, HumoralImmunoglobulin GImmunoglobulin MPeptidesSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, ViralEpitopesImmunoglobulin GImmunoglobulin MPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2AbMapCOVID-19dynamicsELISAepitopemicroarraySARS-CoV-2S protein

Identifiers

PMID35371042
PMCPMC8971992
OpenAlexW4220929987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.